Cinnarizine Avexime - instructions for use, dose, side effects, contraindications

Composition: 25 mg of cinnarizine as an active substance; auxiliary substances - potato starch, low molecular weight polyvinylpyrrolidone (povidone), magnesium stearate, lactose, aerosil (silicon dioxide colloidal).

Description:Tablets are white or white with a creamy shade of color, flat-cylindrical with a bevel.

Pharmacotherapeutic group:The blocker of "slow" calcium channels.

ATX: & nbsp

N.07.C.A.02 Cinnarizine

Pharmacodynamics:

Selective blocker slow calcium channels, reduces the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, lowers the tone of the smooth muscle arterioles. Immediately affecting the smooth muscles of blood vessels, reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with respect to cerebral vessels), without having a significant effect on blood pressure. It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood. Increases muscle resistance to hypoxia.

Pharmacokinetics:

Absorbed in the stomach and intestines. The maximum concentration in the blood plasma after oral administration after 1-3 hours. The connection with plasma proteins is 91%.

It is completely metabolized in the liver (via glucuronation). The half-life is 4 hours. It is excreted in the form of metabolites: 1/3 -tips and 2/3 - with caloric masses.

Indications:

Symptoms of cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration of attention), vestibular disorders (including Meniere's disease: dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinthine origin), prevention of kinetosis ( "road disease" - sea and air sickness), migraine (prevention of seizures).

Violations of peripheral blood circulation: Raynaud's disease, "intermittent" lameness, acrocyanosis, trophic disorders (including trophic and varicose ulcers).

Contraindications:

Hypersensitivity, pregnancy, lactation, children under 5 years.

Carefully:With caution in Parkinson's disease.

Dosing and Administration:

Inside, after eating.

With insufficiency of cerebral circulation: 25 mg three times a day.

If peripheral circulation is disturbed, 50-75 mg three times a day.

With vestibular disorders - 25 mg three times a day.

The maximum recommended dose should not exceed 225 mg (9 tablets) per day. The course of treatment is from several weeks to several months.

In kinetosis ("road" disease): adults - 25 mg for half an hour before the road (if necessary, repeated intake of 25 mg after 6 hours), for children from 5 years - ½ the dose recommended by an adult.

With high sensitivity to the drug, treatment starts with ½ dose, increasing it gradually.

Side effects:

From the nervous system: drowsiness, fatigue, headache, extrapyramidal disorders (limb tremor and muscle tone increase, hypokinesia), depression.

From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.

On the part of the skin: sweating, development of lupus-like syndrome, red flat lichen (extremely rare), skin rash.

Other: allergic reactions, weight gain.

Overdose:

Symptoms: increased severity of side effects, lower blood pressure, vomiting, coma. Treatment: there is no specific antidote, gastric lavage, activated charcoal, symptomatic therapy.

Interaction:Strengthens the depressing effect on the central nervous system of alcohol, sedatives, tricyclic antidepressants. In connection with the presence of antihistamine effect, cinnarizine can affect the result of anti-doping control athletes (false positive result),and also can neutralize positive reactions during skin diagnostic tests (for 4 days before the study treatment should be canceled).

Special instructions:

Patients with Parkinson's disease, the drug is prescribed only in cases when the benefits of cinnarizine treatment outweigh the possible worsening of the course of the underlying disease.

At the beginning of treatment can cause drowsiness, so taking alcohol and simultaneous use of depressants of the central nervous system requires caution.

In connection with the antihistamine effect, the appointment of cinnarizine should be discontinued 4 days before the allergic skin test. Cinnarizine can affect the result in the anti-doping control of athletes (false positive result).

When lactose intolerance, it should be noted that one tablet contains 175 mg of lactose.

With prolonged use, it is recommended that a control laboratory examination of the liver, kidneys, and peripheral blood is recommended.

Effect on the ability to drive transp. cf. and fur:Perhaps the development of drowsiness, especially at the beginning of treatment,therefore, care should be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:

Tablets 25 mg.

Packaging:

10 tablets in a contour cell package. 1,2,3,4,5 or 10 contour mesh packages together with instructions for use in a pack of cardboard.

Storage conditions:

In a dry place protected from light.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-003105/08

Date of registration:24.04.2008

The owner of the registration certificate:Anzhero-Sudzhensky Chemical-Pharmaceutical Plant, LLC Anzhero-Sudzhensky Chemical-Pharmaceutical Plant, LLC

Manufacturer: & nbsp

Anzhero-Sudzhensky Chemical-Pharmaceutical Plant, LLC Russia

Information update date: & nbsp09.10.2015

Illustrated instructions

Instructions

Cinnarizine Avexime (Cinnarizine Avexima)